Cytek Biosciences annual free cash flow
2020
2021
2022
2023
2024
2025
Cytek Biosciences Free Cash Flow (FCF) History (CTKB)
Cytek Biosciences reported −$8.8M in free cash flow for fiscal 2025, a decrease of $30.6M from the previous fiscal year, with a free cash flow margin of −4.35%.
View full Cytek Biosciences company overviewCytek Biosciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$8.8M | −$30.6M | — | −4.35% |
| 2024 | 2024-12-31 | $21.9M | $21.2M | +3352.45% | +10.90% |
| 2023 | 2023-12-31 | $633,000 | $22.6M | — | +0.33% |
| 2022 | 2022-12-31 | −$22.0M | −$22.2M | — | −13.40% |
| 2021 | 2021-12-31 | $266,000 | −$13.3M | −98.05% | +0.21% |
| 2020 | 2020-12-31 | $13.6M | — | — | +14.66% |
Cytek Biosciences quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$849,000 | $620,000 | — | −1.76% |
| Q1 2026 | 2026-03-31 | −$4.9M | −$3.9M | — | −11.11% |
| Q4 2025 | 2025-12-31 | −$1.8M | −$2.9M | — | −2.85% |
| Q3 2025 | 2025-09-30 | −$4.6M | −$16.8M | — | −8.71% |
| Q2 2025 | 2025-06-30 | −$1.5M | −$6.6M | — | −3.22% |
| Q1 2025 | 2025-03-31 | −$974,000 | −$4.4M | — | −2.35% |
| Q4 2024 | 2024-12-31 | $1.1M | −$6.9M | −86.23% | +1.92% |
| Q3 2024 | 2024-09-30 | $12.2M | $17.8M | — | +23.71% |
| Q2 2024 | 2024-06-30 | $5.2M | $9.3M | — | +11.05% |
| Q1 2024 | 2024-03-31 | $3.4M | $1.0M | +44.07% | +7.56% |
| Q4 2023 | 2023-12-31 | $8.0M | $8.3M | — | +13.76% |
| Q3 2023 | 2023-09-30 | −$5.6M | $3.0M | — | −11.60% |
| Q2 2023 | 2023-06-30 | −$4.2M | $6.6M | — | −8.38% |
| Q1 2023 | 2023-03-31 | $2.4M | $4.6M | — | +6.34% |
| Q4 2022 | 2022-12-31 | −$337,000 | −$4.5M | — | −0.70% |
| Q3 2022 | 2022-09-30 | −$8.6M | −$8.5M | — | −21.28% |
| Q2 2022 | 2022-06-30 | −$10.8M | −$5.6M | — | −26.81% |
| Q1 2022 | 2022-03-31 | −$2.3M | −$3.7M | — | −6.45% |
| Q4 2021 | 2021-12-31 | $4.2M | $2.4M | +141.82% | +10.68% |
| Q3 2021 | 2021-09-30 | −$147,000 | — | — | −0.43% |
| Q2 2021 | 2021-06-30 | −$5.2M | — | — | −16.99% |
| Q1 2021 | 2021-03-31 | $1.4M | — | — | +5.88% |
| Q3 2020 | 2020-09-30 | $1.7M | — | — | +6.84% |
Cytek Biosciences free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $13.6M to −$8.8M, a net decrease of $22.4M. Cytek Biosciences's latest reported quarter, Q2 2026, generated −$849,000 in free cash flow, an increase of $620,000 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Cytek Biosciences filings at SEC.gov ↗